论文部分内容阅读
欧洲自2007年1月26日开始实行儿科用药的监管,这极大的改变了欧洲儿科药物的监管环境,并显示出对儿科药物发展的积极影响.随着儿科药物临床试验的不断增多,儿科研究协作网络的优势得以突显.法国已建立了法国儿科研究中心网络(CICPs),为随机对照及其它设计科学的儿科临床研究的发展提供基础构架.该合作网络由整合在教学医院的14个研究中心组成,其目的是开展病理生理学方面的儿科临床研究及儿科药物再评价,并促成临床技术革新.CICP协作网为研究者们提供各种支持,包括临床研究方案的设计和实施,不论是研究者自发的还是企业资助的临床研究.为与GCP指南一致,CICP网络也对正在参与临床研究的患儿及家长提供帮助.新生儿感染治疗(TINN)是FP7项目资助的一个主要协作网.TINN协会包括来自7个欧洲国家在儿科药物评价领域经验丰富的儿科医生、药理学家和临床药师,其主要目的是评价新生儿抗生素和抗病毒药物的说明书外用药.除了科学上的影响,TINN也组织进行教学和项目培训,使其在较高的科学水平和伦理标准下开展儿科临床试验.“,”The European regulation on medicines for pediatric use entered into force on 26 January 2007. It changes dramatically the regulatory environment for pediatric medicines in Europe. The positive impact on pediatric medicine development has been demonstrated. With the increased number of pediatric studies and clinical trials, the advantages of pediatric network are highlighted.France has established the French network of pediatric investigation centers (CICPs) providing infrastructure to facilitate the conduct of randomized trials and other well designed pediatric studies. The network consists of fourteen research centers integrated into teaching hospitals. The aim of the network is to conduct pediatric clinical research in the areas of drug evaluation, pathophysiology, and to contribute to technical innovations. The design of the CICP Network provides support to investigators through the conduct of investigator-initiated or industrially sponsored clinical research protocols. In accordance with Good Clinical Practice guidelines, the CICP network also supports parents and their children during their participation in medical researches.The TINN (Treat infection in neonates) is a thematic network funded by FP7 program. The TINN consortium involves pediatricians, pharmacologists, and pharmacists from seven European countries with extensive experiences in the evaluation of medicines for children. The main objective is to evaluate off-label antibiotics and antivirals in neonates. In addition to the scientific impact, TINN will also demonstrate its educational impact by organizing teaching programs and by conducting pediatric clinical trials with high scientific and ethical standards.